Cell therapy for spinal cord injury by using human iPSC-derived region-specific neural progenitor cells

68Citations
Citations of this article
78Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The transplantation of neural progenitor cells (NPCs) derived from human induced pluripotent stem cells (iPSCs) has beneficial effects on spinal cord injury (SCI). However, while there are many subtypes of NPCs with different regional identities, the subtype of iPSC-derived NPCs that is most appropriate for cell therapy for SCI has not been identified. Here, we generated forebrain- and spinal cord-type NPCs from human iPSCs and grafted them onto the injured spinal cord in mice. These two types of NPCs retained their regional identities after transplantation and exhibited different graft-host interconnection properties. NPCs with spinal cord regional identity but not those with forebrain identity resulted in functional improvement in SCI mice, especially in those with mild-to-moderate lesions. This study highlights the importance of the regional identity of human iPSC-derived NPCs used in cell therapy for SCI.

Cite

CITATION STYLE

APA

Kajikawa, K., Imaizumi, K., Shinozaki, M., Shibata, S., Shindo, T., Kitagawa, T., … Okano, H. (2020). Cell therapy for spinal cord injury by using human iPSC-derived region-specific neural progenitor cells. Molecular Brain, 13(1). https://doi.org/10.1186/s13041-020-00662-w

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free